https://www.ft.com/content/3f113f11-b5ea-4cf3-b2bb-2d9059f6b18c
Atossa Therapeutics Issues Letter To Shareholders From Steven Quay, M.D., Ph.D., The Company’s President And Chief Executive Officer
Atossa Therapeutics, Inc. (NASDAQ:ATOS), a clinical stage biopharmaceutical company developing innovative medicines in areas of significant unmet medical need in oncology with a focus on breast cancer, today announces